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1. Introduction
Alzheimer  is  an  age-dependent  neurodegenerative  process  distinct  from  normal  aging
and characterized morphologically by the presence of  senile  plaques and neurofibrillary
tangles,  which  progress  from  the  brain  stem  and  inner  parts  of  the  temporal  lobes  to
most the telencephalon.
Senile plaques are mainly composed of different species of fibrillar β-amyloid (Aβ), a product
of the cleavage of the β-amyloid precursor protein (APP), and they are surrounded by
dystrophic neurites, reactive astrocytes and microglia. Aβ fibrillar deposits also occur in
diffuse plaques, subpial deposits and in the wall of the cerebral and meningeal blood vessels
in the form of amyloid angiopathy. A substantial part of β-amyloid is not fibrillar but soluble
and forms oligomers of differing complexity which are toxic to nerve cells.
Neurofibrillary tangles are mainly composed of various isoforms of tau protein, which is
hyper-phosphorylated and nitrated. It has an altered conformation and is truncated at different
sites through the action of a combination of several proteolytic enzymes giving rise to species
of low molecular weight which are toxic to nerve cells. Abnormal tau deposition also occurs
in the dystrophic neurites of senile plaques and within the small neuronal processes, resulting
in the formation of neuropil threads.
The mechanisms of disease progression are not completely understood but Aβ initiates the
pathological process in the small percentage of familial cases due to mutations in genes
encoding APP, presenilin 1 and presenilin 2, the latter involved in the cleavage of APP, and
potentiates tau phosphorylation in sporadic cases that represent the majority of affected
individuals (β-amyloid cascade hypothesis). Moreover, Aβ act as a seed of new β-amyloid
production and deposition under appropriate settings, and abnormal tau promotes the
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production and deposition of hyper-phosphorylated tau. Therefore, Aβ and hyper-phos‐
phorylated tau promote the progression of the process and this may occur in an exponential
way once these abnormal proteins are accumulated in the brain.
In addition to these pathological hallmarks, multiple alterations play roles in the degen‐
erative process.  Several genetic factors,  such as apolipoprotein ε4 (APOE4), and external
factors,  such  as  vascular  and  circulatory  alterations  and  repeated  cerebral  traumatisms,
among  others,  facilitate  disease  progression  in  sporadic  forms.  Furthermore,  metabolic
components mainly, but not merely, associated with aging have a cardinal influence, in‐
cluding mitochondrial defects and energy production deficiencies, production of free rad‐
icals  (oxidative  and  nitrosative  reactive  species:  ROS  and  NOS)  and  oxidative  and
nitrosative  damage,  increased  reticulum  stress  damage,  altered  composition  of  mem‐
branes, inflammatory responses and impaired function of degradation pathways such as
autophagy and ubiquitin-proteasome system.
It has been proven that the degenerative process, at least the presence of neurofibrillary tangles,
starts in middle age in selected nuclei of the brain stem and entorhinal cortex, and then
progresses to other parts of the brain. Instrumental stages of Braak cover stages I and II with
involvement of the entorhinal and transentorhinal cortices; stages II and IV also affect the
hippocampus and limbic system together with the basal nucleus of Meynert; and stages V and
VI involve the whole brain although neurofibrillary tangles are not found in selected regions
such as the cerebellar cortex and the dentate gyrus. The distribution of senile plaques is a bit
different as they first appear in the orbitofrontal cortex and temporal cortex and then progress
to the whole convexity.
A concomitant decline in neuronal organization occurs most often in parallel with senile
plaques and neurofibrillary tangles manifested as synaptic dysfunction and synaptic loss, and
neuronal death and progressive isolation of remaining neurons.
An important observation is that about 80% of individuals aged 65 years have Alzheimer-
related changes, at least at stages I-III, whereas only 5% have cognitive impairment and
dementia. About 25% of individuals aged 85 years suffer from cognitive impairment and
dementia of Alzheimer type. Stages I-IV are often silent with no clinical symptoms. Cognitive
impairment and dementia usually occur at stages V and VI when the neurodegenerative
process is very advanced. Importantly, the progression from stage I to stage IV may last
decades, whereas the progression to stages V and VI is much more rapid. Therefore, Alzheimer
is a well-tolerated degenerative process during a relatively long period of time, but it may have
devastating effects once thresholds are crossed. Moreover, clinical symptoms may be compli‐
cated by concomitant vascular pathology.
Several attempts have been made to predict the evolution to disease states. Neuroimaging,
including high resolution and functional magnetic resonance imaging, positron emission
tomography and the use of relative selective markers of β-amyloid and tau deposition in the
brain, together with reduced levels of Aβ and increased index of phospho-tau/total tau in the
cerebrospinal fluid, are common complementary probes (biomarkers) in addition to the data
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provided by the neuropsychological examination. Unfortunately, these tests, at present, detect
relatively advanced stages of the process in pathological terms.
It is very illustrating to visualize under the microscope how a brain at middle stages of the
degenerative process has been working without apparent neurological deficits during life. The
adaptive capacities of the brain in coping with current functions in spite of the decrepitude of
composition and organization resulting from the chronic progression of the degenerative
process are impressive.
Taking into consideration this scenario, it is compulsory to increase understanding of the first
stages of the degenerative process and to act on selective targets before the appearance of
clinical symptoms.
The present review is not a mere list of putative treatments of Alzheimer’s disease (AD) but
rather an approach to learning about observations made on experimental models and early
stages of disease aimed at curbing or retarding disease progression on the basis of definite
rationales. It is also our aim to encourage the consideration of Alzheimer as a degenerative
process not necessarily leading to dementia [1]. This concept has important clinical implica‐
tions as it supports early preventive measures in the population at risk (i.e. persons over 50
years) even in the absence of clinical symptoms.
2. Experimental therapeutic strategies to prevent Alzheimer progression to
Alzheimer Disease (AD) states
Several reviews have focused on various aspects related to habits and dietary elements which
may act as protective factors against AD, including physical and mental exercise, low caloric
intake, various diets with low fat content, and vitamin complements [2, 3]. It is worth noting
that neuropathological studies in old-aged individuals usually present combined pathologies,
and combination of Alzheimer changes and vascular lesions are very common [4]. It is well
documented that vascular pathology potentiates primary neurodegenerative pathology and
that vascular factors may be causative of cognitive impairment and dementia [5]. Therefore,
therapies geared to reduce vascular risk factors are also protective factors against AD clinical
manifestations.
2.1. Targeting Aβ
Most of the current drug development for the prevention or treatment of AD is based on the
β-amyloid cascade hypothesis and aims at reducing the levels of Aβ in the brain. Overpro‐
duction, aggregation and deposition of the Aβ peptide begin before the onset of symptoms
and they are considered an essential early event in AD pathogenesis. Thus, targeting these
early Aβ alterations is assumed to reduce the progression to disease states. The different
strategies developed to achieve this objective include decreasing Aβ production through
modulating secretase activity, interfering with Aβ aggregation, and promoting Aβ clearance.
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2.1.1. Secretase-targeting therapies
APP is processed in the brain exclusively by three membrane-bound proteases, α-, β- and γ-
secretase. Therefore, specifically modifying such enzyme activity should result in a reduction
of Aβ production [6].
• α-secretase activators: α-secretase initiates the non-amyloidogenic pathway by cleaving APP
within the Aβ sequence, thereby preventing the production of Aβ and producing a non-
toxic form of APP derivative which is neuroprotective and growth- promoting [7]. There‐
fore, compounds that stimulate α-secretase activity could become an attractive strategy to
reduce Aβ production. In fact, some indirect methods of promoting α-secretase activity,
such as the stimulation of the protein kinase C (PKC) or Mitogen-activated protein kinases
(MAPK) pathways, the use of α-7-nicotinic acetylcholine (ACh) receptor and 5-hydroxi‐
tryptamine (5-HT) receptor 4 agonists, and γ-aminobutyric acid A receptor modulators,
result in α-secretase-mediated cleavage of APP and reduced Aβ levels in vivo [8]. However,
the development of a direct activator of α-secretase as a drug treatment for AD seems
premature because of the lack of knowledge about the consequences of chronic up-regula‐
tion of α-secretase-mediated cleavage on other substrates [6].
• β-secretase inhibitors: the β-secretase enzyme initiates the amyloidogenic pathway, cleaving
APP at the amino terminus of the Aβ peptide. Further cleavage of the resulting carboxy-
terminal fragment by γ-secretase results in the release of Aβ. β-secretase activity is specifi‐
cally mediated by the β-site APP cleaving enzyme 1 (BACE1), which is also involved in the
processing of numerous substrates in addition to APP. The research of drugs inhibiting
BACE1 activity was encouraged by studies revealing that the expression of mutated BACE1
reduces amyloidogenesis and cognitive impairment in APP transgenic mice [9, 10]. The first
generation of BACE1 inhibitors was peptide-based mimetics of the APP β-cleavage site.
Unfortunately, these compounds exhibited some difficulties because of the large substrate
binding site of BACE1 and because of the difficulty in crossing the blood–brain barrier (BBB)
and penetrating the plasma and endosomal membranes to gain access to the intracellular
compartments where endogenous BACE1 plays its function. Recently, non-peptide small-
molecule BACE1 inhibitors have been reported to improve bioavailability and to lower
cerebral Aβ levels in animal models of AD [11, 12]. However, the involvement of BACE1 in
other important physiological processes raises concerns about minimizing the potential
adverse effects derived from generalized BACE1 inhibition.
• γ-secretase inhibitors (GSIs): γ-secretase is a complex composed of presenilin 1 and presenilin
2 (PS1 and PS2) forming the catalytic core and three accessory proteins, anterior pharynx-
defective 1 (APH-1), nicastrin and presenilin enhancer protein 2 (PEN2). The γ-secretase
complex displays a high degree of subunit heterogeneity and little is known about the
physiological roles of the diverse complexes and how they process different trans-mem‐
brane substrates in addition to APP. This heterogeneity suggests that selective targeting of
one particular subunit might be a more effective treatment strategy than non-selective γ-
secretase inhibition [13]. Thus, removal of APH-1B and APH-1C isoforms in a mouse model
of AD decreased Aβ plaque formation and improved behavioral deficits [14]. A number of
orally bioavailable and brain-penetrating GSIs have been shown to decrease Aβ production
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and deposition in APP mouse models and in humans [15-17]. However, target-based toxicity
of GSIs has been a major obstacle to the clinical development of these compounds. In fact,
two large Phase III clinical trials of Semagacestat, the only GSI extensively studied in AD,
were prematurely interrupted because of the observation of detrimental cognitive and
functional effects of the drug [18]. Several dozen γ-secretase substrates have been identified,
including Notch1 trans-membrane receptor, which plays an important role in a variety of
developmental and physiological processes by controlling cell fate decisions. To overcome
these toxicity issues, pharmaceutical companies have been trying to develop a second
generation of ‘Notch-sparing’ GSIs, which revealed beneficial effects in in vitro and in animal
models of AD [19-21]. They are currently under clinical studies. Such ‘Notch-sparing’ GSIs
have higher pharmacological selectivity than the first GSIs probably due to the distinct
binding to the substrate docking site on γ-secretase of Notch and APP. Identification of
several γ-secretase inhibitors has been reviewed elsewhere [22].
2.1.2. Aβ degrading enzymes
Almost 20 enzymes are currently known to contribute to Aβ degradation in the brain, although
the most studied are two zinc metalloproteases, neprilysin (NEP) and insulin-degrading
enzyme (IDE). NEP is one of the major Aβ-degrading enzymes in the brain [23] and NEP levels
are decreased in the brain of AD and animal models [24, 25]. Lentiviral delivery of the NEP
gene to the brain of AD transgenic mice reduced Aβ pathology [26]. A number of subsequent
studies with NEP and other related peptidases such as endothelin-converting enzymes 1 and
2 (ECE-1 and ECE-2) further supported this observation [27]. Similarly, over-expression of IDE
in neurons significantly reduces brain Aβ levels, prevents Aβ plaque formation and its
associated cytopathology, and rescues the premature lethality present in these particular APP
transgenic mice [28]. A growing body of evidence has been accumulated supporting the
potential therapeutic properties of IDE in AD [29].
Other specific Aβ-cleaving proteases such as angiotensin-converting enzyme (ACE), matrix
metalloproteinase-9 (MMP-9) and the serine protease plasmin, which have distinct sub-cellular
localizations and differential responses to aging, oxidative stress and pharmacological agents,
are also potential candidates to become novel therapeutic strategies for AD prevention and
treatment [27].
Targeting the delivery of these compounds to the brain remains a major challenge. The most
promising current approaches include peripheral administration of agents that enhance the
activity of Aβ-degrading enzymes and direct intra-cerebral release of enzymes by convection-
enhanced delivery. Genetic procedures geared at increasing cerebral expression of Aβ-
degrading enzymes may offer additional advantages [30].
2.1.3. Decreasing Aβ aggregation
Compounds that suppress the aggregation or reduce the stability of Aβ oligomers may bind
monomers in order to attenuate formation of both the oligomeric and senile plaque fibrillar
Aβ constituents. One of the amyloid-binding drugs more extensively studied in animal models
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and AD patients is tramiprosate (3-amino-1-propanesulfonic acid; Alzhemed). Tramiprosate
was effective in reducing Aβ polymerisation in vitro, inhibiting the formation of neurotoxic
aggregates, and decreasing Aβ plaque formation in animal models [31]. However, recent phase
III clinical trials did not produce any significant improvement in cognition in AD patients
chronically treated with tramiprosate in spite of the significant reduction in hippocampus
volume loss [32]. Similarly, some other compounds known to inhibit Aβ aggregation and fibril
formation showed positive effects in animal and in vitro models of AD but failed to produce
conclusive results in human clinical trials. This is the case with scyllo-inositol and PBT2. Scyllo-
inositol inhibited cognitive deficits in TgCRND8 mice and significantly ameliorated disease
pathology, even in animals at advanced stages of AD-like pathology, without interfering with
endogenous phosphatidylinositol lipid production [33, 34]. Yet a phase II clinical trial failed
in supporting or refuting a benefit of scyllo-inositol in mild to moderate AD patients [35]. PBT2
is a copper/zinc ionophore which targets metal-induced aggregation of Aβ. When given orally
to two models of Aβ-bearing transgenic mice, PTB2 was able to markedly decrease soluble
brain Aβ levels within hours and to improve cognitive performance within days [36]. These
results correlated with a rapid cognitive improvement in AD patients in a recent phase IIa
clinical trial [37], an observation that argues for large-scale testing of PBT2 for AD.
Another promising recent experimental approach is the use of dendrimers as agents interfering
with Aβ fibrilization. Dendrimers are globular branched polymers, typically symmetric
around the core with a spherical three-dimensional morphology. Their chemical structure
allows dendrimers to couple to active amyloid species through hundreds of possible sites.
Dendrimers have been shown to be able to modulate Aβ peptide aggregation by interfering
in different ways with the polymerization process, including fibril breaking, inhibition of fibril
formation and acceleration of fibril formation [38, 39]. However, some dendrimers assayed in
amyloidogenic systems are toxic to cells. The development of non-toxic glycodendrimers,
which reduce toxicity by clumping fibrils together [40], opens the possibility of using den‐
drimers with low intrinsic toxicity in AD. Additional difficulties in dendrimer administration
involve the crossing of the BBB so as to reach their targets in the brain.
2.1.4. Facilitating Aβ clearance: Immunotherapy against Aβ
Active and passive immunotherapy against Aβ peptide has been explored as a therapeutic
approach to stimulate the clearance of Aβ in the brain at the preclinical and clinical stages of
the disease in animal models. Pioneering studies proved that vaccination of young APP
transgenic mice using a synthetic aggregated form of Aβ42 (AN-1792) effectively prevented
Aβ plaque formation, neuritic dystrophy and astrogliosis in adult brains [41]. Subsequent
studies further demonstrated improvement of memory loss in those APP transgenic mice
vaccinated against Aβ [42, 43]. Different models, methods and ways of administration showed
the beneficial effects of active and passive immunization in animal models of AD. Neverthe‐
less, the phase II trial in humans was discontinued because of the occurrence of aseptic
meningoencephalitis in a number of cases [44-46]. The cause of the meningoencephalitis was
a concomitant T-cell-mediated autoimmune response [45, 46]. Moreover, several studies in
APP transgenic mice have reported an increased risk of microhemorrhages at sites of cerebro‐
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vascular Aβ deposits [47]. Yet important conclusions were drawn from the studies in humans:
immunization reduced the number of Aβ plaques and the number of dystrophic neurites,
including tau phosphorylation around plaques, but not Aβ burden in blood vessels; however,
immunization increased intracerebral levels of soluble Aβ [48-50].
New  vaccines  containing  immunodominant  B-cell  epitopes  of  Aβ  [51]  and  recognizing
other Aβ residues [52, 53], and the use of passive immunization with deglycosylated an‐
tibodies  [54]  have demonstrated positive  effects  in  the  clearance of  Aβ without  causing
inflammatory  response  or  hemorrhages  in  animal  models  of  AD  [55].  These  findings
have prompted new clinical  trials  which are currently evaluating the toxicity and effec‐
tiveness of at  least  ten vaccines in mild-to-moderate AD patients worldwide [56].  While
vaccines hold great hope as AD therapies, it  is important to stress that immunization at
pre-symptomatic stages is essential in order to avoid the irreversible brain damage occur‐
ring even at the early symptomatic stages [57].
2.2. Targeting tau
The interest in tau-related therapies is still emerging and very few clinical studies are under‐
way, in part because of the difficulties encountered with anti-Aβ strategies that captured most
efforts in the two last decades, but also because of the challenging identification of tractable
therapeutic targets related to tau. Current research in the prevention of tau pathology devel‐
oped in animal models of AD has resulted in some promising results [58]. Main rationales in
tau pathology are based on: 1: inhibition of tau aggregation, 2: reduction of tau phosphoryla‐
tion by inhibition of tau kinases or activation of phosphatases (including PP2a activity), 3:
reduction of tau levels by increasing tau degradation or by using active immunization, and 4:
stabilization of microtubule [59].
2.2.1. Inhibition of tau aggregation
Some compounds that are known to inhibit tau-tau interactions have been tested as agents
aimed at slowing Alzheimer progression to disease states. Among them, phenothiaziazine
methylene blue inhibits tau-tau interactions, is neuroprotective and is able to facilitate soluble
tau clearance in a mouse model of human tauopathy [60, 61]. Moreover, phenothiaziazine
methylene blue has shown beneficial effects in a phase II clinical trial conducted for one year
[62]. Another promising inhibitor of tau aggregation is the immunosuppressant FK506, which
exerts its beneficial effects in transgenic mice by directly binding tau to the FK506 binding
protein 52 and by modulating microglial activation [63, 64].
However, some concerns araise from the use of tau aggregation inhibitors in that at least some
tau aggregation inhibitors enhance the formation of potentially toxic tau oligomers [65].
2.2.2. Reduction of tau hyperphosphorylation
Kinases which participate in the phosphorylation of tau and phosphatases which dephos‐
phorylate tau are clear putative therapeutic targets for AD [66]. The most widely studied tau
kinases in AD pathogenesis are Glycogen synthase kinase 3 beta (GSK-3β) and Cyclin-
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dependent kinase (CDK5) [67, 68]. Several GSK-3β inhibitors, including lithium, aloisines,
flavopiridol, hymenialdisine, paullones, and staurosporine, are under active investigation and
development [69]. Lithium revealed some promising results when administered in transgenic
mice expressing the P301L human 4R0N tau at pre-symptomatic stages; it improved behavior
and reduced the levels of phosphorylation, aggregation and insoluble tau in transgenic mice
[70]. However, several concerns have arisen in relation of the use of GSK-3β in the treatment
of AD; these are based on the fact that lithium lacks specificity over GSK-3β activity and it has
a narrow safety margin [71]. Moreover, GSK-3β acts on multiple metabolic pathways that are
also impaired with unknown consequences after chronic treatment.
CDK5 inhibitors prevent Aβ-induced tau hyper-phosphorylation and cell death in vitro [72,
73]. A recent in vivo study further demonstrates that inhibition of CDK5 activates GSK-3β,
which plays a more dominant role in overall tau phosphorylation than does CDK5 [74]. Thus,
considering that CDK5 inhibitors might be unable to reverse abnormal hyper-phosphorylation
of tau and treat neurofibrillary degeneration because of the interplay between CDK5 and
GSK-3β, as well as the essential role played by CDK5 in multiple cell signaling pathways [75],
the interest of such compounds as a tau-targeting therapy for AD is limited.
Another approach to reverse tau hyper-phosphorylation is up-regulation of tau phosphatases
[66]. The major tau phosphatase, PP2A, is down-regulated in AD brain. In consequence, correct‐
ing PP2A levels is the primary target to be considered. Among the compounds known to re‐
verse PP2A inhibition, memantine is the most outstanding because of the demonstrated clinical
benefit in AD. In an animal model, memantine was able to reverse okadaic acid–induced PP2A
inhibition and to prevent tau hyper-phosphorylation, restoring MAP2 expression [76]. Similar‐
ly, melatonin has also been shown to restore PP2A activity and reverse tau hyper-phosphoryla‐
tion, both in vitro and in experimental animals [77]. One important concern in considering PP2A
as a potential therapeutic target is that all protein phosphatases have much broader substrate
specificities than protein kinases. Thus, more undesirable effects might be expected than when
using kinase inhibitors [66]. A further intriguing point is that PP2A function and activity de‐
pend on multiple subunits and cofactors which are dysregulated in AD [78]. It is not clear how
all these elements can be resolved to result in maintained balanced activity.
2.2.3. Reduction of tau levels
A potential alternative to modulate tau phosphorylation is reducing overall tau levels [58].
Experiments carried out in genetically-modified mice expressing reduced tau levels revealed
diminished cognitive impairment and Aβ-induced neuronal damage [79-81]. An alternative
method to reduce tau levels could is by targeting molecules that regulate the expression or
clearance of tau. Tau can be degraded via the ubiquitin-proteasome system and the lysosomal
pathways. Reduction of the levels of the tau ubiquitin-ligase CHIP increases the accumulation
of tau aggregates in JNPL3 mice, suggesting that increasing the expression of CHIP could result
in reduced tau levels [82]. Acetylation of tau inhibits its degradation [83], alters its microtubule
binding, and enhances aggregation [84]. Thus, the combination of tau acetylation inhibition
and ubiquitination-proteasome enhancement might produce a synergy that lowers the levels
of pathogenic tau species.
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Tau degradation can also be enhanced by immunization. Active immunization targeting
phosphorylated tau reduces filamentous tau inclusions and neuronal dysfunction in JNPL3
transgenic mice [85, 86]. Moreover, recent studies have raised the possibility of modulating
tau pathology by passive immunization revealing reduced behavioral impairment and tau
pathology in two transgenic models of taupathies [87].
2.2.4. Microtubule stabilizers
Since microtubule disruption occurs in several models of AD and is associated with tau
dysfunction, microtubule stabilizers have been assayed in preclinical and clinical trials for AD
[88]. The anti-mitotic drug paclitaxel prevents Aβ-induced toxicity in cell culture [89], as well
as axonal transport deficits and behavioral impairments in tau transgenic mice [90]. Unfortu‐
nately, paclitaxel is a P-glycoprotein substrate and it has very low capacity to cross the BBB,
making it unsuitable for the treatment of human tauopathies. Epothilone D, which has better
BBB permeability, improves microtubule density and cognition in tau transgenic mice [91].
Finally, the peptide NAP stabilizes microtubules and reduces tau hyper-phosphorylation [92].
NAP can be administered intra-nasally and has shown promising results in a phase II clinical
trial [93].
2.3. Oxidative stress
Several pieces of evidence demonstrate that oxidative stress precedes other hallmarks of the
neurodegenerative process in human brains and animal models of AD, including Aβ deposi‐
tion, NFT formation, and metabolic dysfunction and cognitive decline. It plays a functional
role in the pathogenesis of the disease [94-100]. These findings sustain the possibility of using
anti-oxidants in the prevention and treatment of Alzheimer [101, 102]. Several studies in AD
transgenic mouse models support the potential beneficial effect of antioxidant compounds as
preventive drugs.
2.3.1. Naturally-occurring anti-oxidants
Several nutritional antioxidants such as resveratrol, curcumin, epigallocatechin gallate, L-
acetyl-carnitine, RRR-α-tocopherol (vitamin E) and ascorbic acid (vitamin C) have been tested
to counteract oxidative stress-induced brain damage in AD.
• Resveratrol is a polyphenolic compound found in grapes, berries and peanuts with well
known anti-oxidant, anti-cancer, anti-inflammatory and estrogenic activities. In vitro and
animal experiments reveal that resveratrol protects against Aβ toxicity by promoting the
non-amyloidogenic  cleavage of  APP,  thus enhancing the clearance of  Aβ peptides  by
promoting  their  degradation  through  the  ubiquitin-proteasome  system,  as  well  as
reducing  neuronal  damage  by  decreasing  the  expression  of  inducible  nitric  oxide
synthase (iNOS) and cyclooxigenase 2 (COX-2), and the pro-apoptotic factors Bax and
c-Jun N-terminal kinase (JNK). Moreover, the capacity of resveratrol to induce the over-
expression of sirtuins, proteins having a role in cell survival, probably contributes to its
neuroprotective effect [103, 104].
Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States
http://dx.doi.org/10.5772/54783
259
• Curcumin is a polyphenolic compound present in the rhizome of Curcuma longa, commonly
used as a spice to color and flavor food, which has anti-inflammatory, anti-carcinogenic and
anti-infectious properties. The first evidence of a protective role of curcumin in AD was
derived from epidemiological studies based on populations subjected to a curcumin-
enriched diet. Additionally, in vitro studies have shown that curcumin protects neurons
from Aβ toxicity whereas the use of AD transgenic mouse models show that curcumin
suppresses inflammation and oxidative damage as well as accelerating the Aβ rate of
clearance and inhibiting Aβ aggregation. Curcumin is considered a bi-functional anti-
oxidant because it is a direct scavenger of oxidants as well as a long-lasting protector
promoting the expression of cytoprotective proteins through the induction of Nrf2-
dependent genes [105, 106]. Regrettably, no significant improvement in cognitive function
between placebo and curcumin-treated groups has been observed in the only two clinical
trials carried out until now [107].
• Epigallocatechin gallate (EGCG) is a polyphenolic flavonoid encountered in green tea. Human
epidemiological and animal data suggest that tea may decrease the incidence of dementia
and AD. EGCG has been demonstrated to exert its neuroprotective activity by reducing
Aβ production and inflammation, and increasing mitochondrial stabilization, iron chelation
and ROS scavenging [108]. However, to date no clinical trials have been performed to verify
whether EGCG neuroprotective/neurorestorative actions can be successfully translated into
human beings.
• Acetyl-L-Carnitine (ALC) is a natural compound found in red meat whose biological role is
to facilitate the transport of fatty acids to the mitochondria. Thus, the main mechanism of
action of ALC is the improvement of mitochondrial respiration, which allows the neurons
to produce the necessary ATP to maintain normal membrane potential. Yet ALC is neuro‐
protective through a variety of additional effects, including an increase in protein kinase C
activity and modulation of synaptic plasticity by counteracting the loss of NMDA receptors
in the neuronal membrane and by increasing the production of neurotrophins [105].
Moreover, ALC reduces Aβ toxicity in primary cortical neuronal cultures by increasing both
heme-oxygenase 1 (HO-1) and heat-shock protein 70 (Hsp70) expression, probably through
transcription factor Nrf2. In two clinical studies, ALC administered for one year significantly
reduced cognitive decline in early-onset AD patients [109, 110] thus sustaining the potential
use of ALC in AD prevention and treatment at early stages.
• RRR-a-tocopherol (Vitamin E) is probably the most important lipid-soluble natural antioxi‐
dant in mammalian cells. Most vegetable oils, nuts and some fruits are important dietary
sources of vitamin E. The interest in evaluating its potential beneficial properties in AD is
also sustained by its known ability to cross the BBB and to accumulate in the central nervous
system. Deficiency in the α-tocopherol transfer protein mediating vitamin E activity induces
an increase in brain lipid peroxidation, earlier and more severe cognitive dysfunction, and
increased Aβ deposits in the brain of Tg2576 mice; this phenotype was ameliorated with
vitamin E supplementation [111]. However, although epidemiological studies have
demonstrated that increasing the intake of fruit and vegetables rich in vitamins prevents or
retards the onset of AD, clinical trials for vitamin E treatment have revealed paradoxical
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results: whereas vitamin E supplementation partially prevents the memory loss associated
with the progression of the disease in some cases, the same treatment was detrimental in
others [112].
• Ascorbic acid (Vitamin C) is an essential nutrient since it acts as a cofactor in elemental
enzymatic reactions, but in contrast to most of organisms, humans are not able to synthesize
ascorbic acid. The main dietary source of vitamin C is fresh fruit and vegetables. The main
interest in vitamin C for the treatment of neurodegenerative processes is related to its potent
anti-oxidant properties. Some studies have revealed that vitamin C supplementation
reduces oxidative stress, and mitigates Aβ oligomer formation and behavioral decline, but
it did not decrease plaque deposition in AD mouse models [113, 114]. Despite epidemio‐
logical studies reporting reduced prevalence and incidence of AD in consumers of vitamin
supplements [115], meta-analyses revealed the risks of chronic consumption of high doses
of vitamin C thus discouraging its routine use in AD. [116]
• Egb76 is a standardized Ginkgo biloba extract already approved in some countries as
symptomatic treatment for dementia although the evidence for its effectiveness remains
inconclusive [117]. However, Egb761 has anti-oxidant properties, inhibits Aβ oligomeriza‐
tion in vitro, reduces impaired memory and learning capacities and enhances hippocampal
neurogenesis in AD transgenic mice [118]. For these reasons, Ginkgo biloba extract is currently
under evaluation as a preventive drug in AD.
In spite of the experimental evidence of beneficial effects of natural anti-oxidants in cultured
cells and transgenic models, clinical studies have demonstrated only minimal effect in humans
probably due to the bioavailability and pharmacokinetics of these substances [102, 105]. What’s
more, a slight acceleration in cognitive decline has been observed in patients treated for 16
weeks with a cocktail of natural antioxidants [119].
2.3.2. Mitochondrial antioxidants
In contrast to other antioxidants, those designed to target the free radical damage to mito‐
chondria provide greater therapeutic potential.
• Lipoic  acid  (LA)  is  a  naturally-occurring  precursor  of  an  essential  cofactor  of  many
mitochondrial  enzymes,  including  pyruvate  dehydrogenase  and  alpha-ketoglutarate
dehydrogenase,  which is  found in almost  all  foods.  LA has been shown to present  a
variety of properties that can interfere with pathogenic processes of AD. LA increases
ACh production, stimulates glucose uptake, protects against Aβ toxicity, chelates redox-
active  transition  metals,  scavenges  reactive  oxygen  species  (ROS)  and  induces  anti-
oxidant protective enzymes probably through the activation of the transcription factor
Nrf2.  Via  the  same  mechanisms,  down-regulation  of  redox-sensitive  inflammatory
processes is also achieved [120]. Data from cell culture and animal models suggest that
LA  can  be  combined  with  other  dietary  anti-oxidants  to  synergistically  decrease
oxidative stress,  inflammation, Aβ levels,  and thus provide a combined benefit  in the
treatment of AD. However, clinical benefits after LA administration were quite small in
patients with mild or moderate dementia [121].
Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States
http://dx.doi.org/10.5772/54783
261
• N-acetyl-cysteine (NAC) is a precursor of glutathione (GSH), the most abundant endogenous
anti-oxidant. NAC acts itself as an anti-oxidant by directly interacting with free radicals, as
well as by increasing GSH levels. NAC protects against Aβ-induced cognitive deficits by
decreasing the associated oxidative stress and related neuroinflammation, but also by
activating anti-apoptotic signaling pathways in neuronal cultures [122]. Late-stage AD
patients supplemented with NAC over a period of six months showed significantly
improved performance in some cognitive tasks, although levels of oxidative stress in
peripheral blood did not differ significantly from untreated patients [123].
• Coenzyme Q10(CoQ10) is a small electron-carrier of the respiratory chain with anti-oxidant
properties due to its role in carrying high-energy electrons from complex I to complex II
during oxidative phosphorylation. CoQ10 and its analogues, idebenone and mitoquinone
(or MitoQ), have been widely used for the treatment of mitochondrial disorders, as well as
for the treatment of Friedreich’s ataxia, and they are also being tested in other neurodege‐
nerative disorders such as amyotrophic lateral sclerosis, and Huntington’s, Parkinson’s and
Alzheimer’s diseases [124]. CoQ10 reduces oxidative stress damage and Aβ plaque burden,
and ameliorates behavioral performance in mouse models of AD [125, 126]. However,
CoQ10 presents two major weaknesses. First, the function of the enzyme is entirely depend‐
ent on the electron transport chain (ETC) which is usually damaged in AD mitochondria.
Second, CoQ10 does not efficiently cross the BBB when administered systemically, being
unable to directly protect neurons from damage. Consequently, CoQ10 derivatives such as
MitoQ, which is a more soluble compound able to penetrate the BBB and that does not
depend on ETC, are seen to offer more promising results [127].
2.4. Inflammation
There is a general consensus that neuroinflammation is a prominent feature in AD with
activated microglia being one of the main manifestations. Neuroinflammation is a complex
process that has both beneficial effects, in terms of maintaining brain homeostasis after various
kinds of insults, and detrimental effects when sustained chronically [128]. This latter situation
is what occurs in AD, in which neuroinflammation is driven by different mechanisms includ‐
ing Aβ production and plaque formation, tau pathology, oxidative stress, and autocrine and
paracrine release of cytokines and other inflammatory molecules which contribute to a feed-
forward spiral favoring the self-propagation of neuroinflammation.
Early epidemiological studies suggesting that long-term use of antiinflammatories might
reduce the risk for developing AD [129] prompted several studies designed to evaluate the
preventive properties of non-steroid anti-inflammatory drugs (NSAIDs). The main NSAID
mechanism of action is to inhibit the activity of cyclooxigenase-1 and -2 (COX-1 and COX-2)
which are the enzymes responsible of the production of prostaglandins and other inflamma‐
tory agents [130]. The administration of the NSAID ibuprofen at early stages of the pathological
process resulted in the reduction of the Aβ burden, dystrophic neurites and activated microglia
in at least three different AD transgenic models [131-134]. Another study indicated that
ibuprofen was effective even in older mice once lesions are well established [135]. Other
NSAIDs such as indomethacin and nimuselide exhibit milder effects compared to ibuprofen
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in the Tg2576 mice [136, 137]. In contrast, the selective COX-2 inhibitor celecoxib failed to
reduce the inflammatory burden and, even worse, increased the Aβ42 levels when administered
to young Tg2576 mice [138].
In spite of the promising results in animal models and the data from retrospective human
epidemiological studies identifying long-term use of NSAIDs as being protective against AD,
prospective clinical trials have not confirmed the efficiency of this group of drugs in the
amelioration of symptoms and in the progression of AD [139].
Other anti-inflammatory agents such as trifusal have been shown to be beneficial in certain
AD transgenic mice models [140].
2.5. Energetic failure: Metabolic deficiency and mitochondrial impairment
Several findings indicate that brain glucose hypometabolism, deficient bioenergetics and
mitochondrial dysfunction precede clinical symptoms in AD [1, 141-143]. The energetic failure
observed even in the prodromal phase of the Alzheimer process is thought to be produced by
the combination of mitochondria dysfunction, alteration of energy metabolism at pore-
mitochondrial level, and increase in energetic demands of altered nerve cells. Thus, strategies
to improve brain energy supply and to preserve mitochondrial functions becomes relevant in
the prevention of progression to disease states [1, 144-146].
2.5.1. Metabolic deficiency
The primary fuel for the brain under normal conditions is glucose, whereas the energetic
contribution made by fatty acids is minor. Therefore, facilitation of energy metabolism and
energy availability has been assayed in animal models and AD by facilitating glucose metab‐
olism and shifting towards the use of alternative fuels.
• Targeting reduced glucose metabolism: Reduction in the utilization of glucose in AD [147] can
be due to several causes including deficient insulin signaling, impairment in glucose
transport mechanisms and dysfunction in glucolysis. Preclinical studies in animal models
of AD have revealed some beneficial effects of anti-diabetic treatments. Thus, the use of the
insulin sensitizer rosiglitazone, an activator of peroxisome-proliferator-activated receptor
gamma (PPARγ) receptor, resulted in the rescue of behavioral deficits and insulin respon‐
siveness in Tg2576 mice [148, 149]. Similarly, exendin-4, an antidiabetic agent that stimulates
the insulin signaling pathway through activation of glucagon-like peptide -1 (GLP1)
receptors, shows beneficial effects in AD, and reduces brain soluble Aβ levels, amyloid
plaque burden, and cognitive impairment in treated APP/PS1 transgenic mice [150, 151].
Therefore, it seems that the positive effects of targeting insulin signaling in AD are related
to the role played by insulin receptor in memory formation, inflammation and Aβ neuro‐
protective effects rather than to the facilitation of glucose transport into the brain [149, 150].
This hypothesis seems also to be supported by a recent study revealing that insulin did not
ameliorate the disruption of energetic homeostasis induced by Aβ oligomers in cultured
neurons [152]. In the end, clinical trials designed to test whether PPARγ agonists could be
beneficial in AD patients provided negative results [153].
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• Shift to alternative energy source: Under metabolically challenging conditions neurons can
utilize acetyl-CoA generated from ketone body metabolism, produced distally in the liver
or locally in the brain by glial cells. In this way, ketone bodies can bypass defects in glucose
metabolism and enter the tricarboxylic acid cycle in the mitochondria of neurons as a source
of ATP. The use of ketogenic diets reduces Aβ40 and Aβ42 levels in young AD transgenic
mice [154] and enhances mitochondrial bioenergetic capacity, reducing Aβ generation and
increasing mechanisms of Aβ clearance in a mouse model of AD [155]. The ketogenic
compound AC-1202 administered in patients with AD has shown a significant improvement
in some cognitive parameters more notable in individuals APOE4(-) [156]. Another possible
alternative source of ATP is creatine. Preliminary studies have shown that creatine has
protective effects against Aβ in vitro [157] and against injury in vivo by maintaining ATP
levels and mitochondrial function [158], suggesting a potential therapeutic effect of creatine
supplementation in AD.
2.5.2. Mitochondrial dysfunction
In addition to the already discussed antioxidant compounds, other potential drugs targeting
mitochondrial dysfunction in AD are available. Several findings point towards a role for Aβ
toxicity in the mitochondrial dysfunction found in AD.
The  progressive  Aβ  accumulation  in  mitochondria  is  associated  with  diminished  enzy‐
matic  activity  of  respiratory  chain  complexes  (III  and  IV)  and  reduction  in  the  rate  of
oxygen consumption,  contributing to  cellular  dysfunction in AD [159].  Aβ in mitochon‐
dria  binds  to  Aβ-binding  alcohol  dehydrogenase  (ABAD)  to  block  ABAD  activity,  in‐
creasing the production of ROS, reducing the mitochondrial membrane potential and the
activity of the respiratory chain complex IV, and ultimately leading to a decrease in ATP
levels [160]. In fact, double transgenic mice over-expressing mutated APP and ABAD ex‐
hibit  exaggerated oxidative stress and memory impairment [160].  Therefore,  compounds
designed  to  block  Aβ-ABAD  interactions  are  considered  putative  therapeutic  agents  in
AD. In line with this hypothesis, a recent study has shown that AG18051, a novel small
ABAD-specific compound inhibitor,  partially blocked the Aβ-ABAD interaction, prevent‐
ed the Aβ42-induced down-regulation of ABAD activity and protected cultured neurons
against  Aβ42  toxicity  by  reducing  Aβ42-induced  impairment  of  mitochondrial  function
and oxidative stress [161]. Furthermore, the introduction of an ABAD-decoy peptide into
transgenic  APP  mice  reduces  Aβ-ABAD  interaction  and  protects  against  Aβ-mediated
mitochondrial toxicity [162].
Another line of research suggests that drugs that activate ATP-sensitive potassium (KATP)
channels  present  in  the  mitochondrial  inner  membrane  exhibit  therapeutic  potential  in
the treatment of AD, as KATP  channels are activated when cellular ATP levels fall  below
a critical  value thereby reducing excitability so as to maintain ion homeostasis  and pre‐
serve ATP levels [163].  Long-term administration of diazoxide improves neuronal bioen‐
ergetics,  suppresses  Aβ  and  tau  pathologies,  and  ameliorates  memory  deficits  in  the
3xTgAD mouse model of AD [164].
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Finally,  another potential  drug in the treatment of  AD that  acts  on mitochondrial  path‐
ways  is  latrepirdine,  also  known as  Dimebon™ [165].  Latrepirdine  reduces  Aβ-induced
mitochondrial impairment and increases the threshold of inductors to mitochondrial pore
transition, making mitochondria more resistant to lipid peroxidation and increasing neu‐
ronal survival in vitro [166-168]. The interest in developing latrepirdine as a drug against
AD is also supported by its multiple potential mechanism of action apart from mitochon‐
drial  effects,  including  anti-excitotoxic  agent,  inhibitor  of  AChE,  channel-regulatior  and
neurotrophic  stimulator  [165].  A preliminary clinical  trial  revealed that  latrepirdine was
safe  and well  tolerated,  and significantly  improved the  clinical  course  of  the  disease  in
patients with mild-to-moderate AD [169].  Current phase III clinical trials are already be‐
ing conducted [165].
2.6. Neurotransmitter dysfunction
The alteration of several transmitter systems is assumed to trigger both cognitive and neuro‐
psychiatric symptoms in AD. A number of post-mortem studies indicate that neurotransmitter
systems are not uniformly affected in AD. Thus, while cholinergic, serotonergic and glutama‐
tergic deficits are present at relatively early stages of AD, dopaminergic and GABAergic
systems appear to be affected later [170].
2.6.1. Cholinergic system
A large body of evidence has shown that basal forebrain cholinergic neurons are vulnerable
to AD leading to a progressive cholinergic denervation of the cerebral neocortex [171, 172].
Taking into account the involvement of this system in the cognitive processing of memory and
attention, the current attempts in cholinergic therapy in AD are justified [172, 173]. The various
cholinergic strategies include the use of ACh precursors, inhibitors of cholinesterases, mus‐
carinic and nicotinic agonists, and ACh releasers, in addition to the rescue of cholinergic
function by nerve growth factor (NGF) which is reviewed in section 2.8.
• ACh precursor. Animal studies report that choline and lecithin increased the production of
brain ACh which argues for their use in the treatment of cholinergic deficits in AD. However,
evidence from randomized trials did not sustain this hypothesis [174].
• Cholinesterase inhibitors (ChEIs). Physostigmine, tacrine and derivatives donepezil, galanta‐
mine and rivastigmine have been tested in AD patients during the last three decades. Their
therapeutic properties have been profusely reviewed [172, 175-177] and for this reason a
detailed revision of ChEIs is beyond the scope of this chapter. Nevertheless, it is worth
briefly indicating additional mechanisms of action of these compounds beyond inhibition
of cholinesterases, including increase of nicotinc ACh receptor expression, facilitation of
APP processing and attenuation of Aβ-induced toxicity [173, 178]. In spite of the fact that
their efficacy has been proved in several clinical trials, only approximately 50% of patients
respond positively. This limited effect of ChEIs on cognitive decline, together with the
occurrence of undesirable side-effects such as diarrhea, nausea, insomnia, fatigue and loss
of appetite, reduces the therapeutic capacities of ChEIs.
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• Muscarinic receptor 1 agonist. The cholinergic deficiency in AD appears to be mainly pre-
synaptic. Thus, the pharmacological stimulation of the post-synaptic M1 muscarinic
receptors, which are preserved until late stages of AD, may balance the degeneration of pre-
synaptic cholinergic terminals unable to properly synthesize and release ACh [173]. In fact,
the selective M1 agonist AF267B reduces memory impairment, Aβ42 levels, and tau hyper-
phosphorylation in AD triple transgenic mice [179], corroborating some early studies in
vitro [180, 181]. This selective agonist is currently under clinical evaluation for safety and
tolerability and a number of other M1 agonists are being investigated [173].
• Nicotinic agonists. Preclinical studies in animal models and some pilot studies in AD have
shown that the activation of pre-synaptic nicotinic ACh receptors may reduce cognitive
impairment by increasing ACh release and may have beneficial effects on Aβ metabolism
[182, 183]. Thus, chronic nicotine treatment results in a significant reduction in plaque
burden and in cortical Aβ concentrations in Tg2575/PS1-A246E mice [184]. However,
nicotine exacerbates tau pathology in 3xTg-AD mice [185]. These apparently contradictory
results may be due to the presence of several subtypes of nicotinic receptors, the activation
of which may have disparate effects in AD. Therefore, more specific nicotine agonists are
needed to act exclusively on determinate subtypes of nicotinic receptor [186]. In this line,
α7 nAChR gene delivery into mouse hippocampal neurons leads to functional receptor
expression and improves spatial memory-related performance and hyperphosphorylation
of tau [187]. Regarding α4β2 nicotinic receptor, the selective agonist cytisine inhibits Aβ
cytotoxicity in cortical neurons [188].
• ACh releasers. Facilitation of ACh release can be achieved with depolarizing agents of the
cholinergic neurons acting via potassium-channel blockade as happens with linopirdine
and analogues [189] or by the blockade of the pre-synaptic inhibitory M2 muscarinic
receptor via specific antagonists [190, 191]. However, clinical trials using linopirdine did not
demonstrate effectiveness in improving cognitive function [192]. On the other hand, certain
selective M2 antagonists, such as SCH-57790 and SC-72788, restore memory impairments
in animal models that mimic to some extent the cholinergic failure in AD [193]. It must be
kept in mind that the potential benefit of M2 antagonists is limited because of the progressive
pre-synaptic cholinergic degeneration in AD and because of the possible side-effects derived
from the blockade of peripheral M2 receptors including cardiac M2 receptors.
2.6.2. Glutamatergic system
Low concentrations of Aβ oligomers are able to activate certain glutamate receptors including
NMDA receptors. The activation of NMDA receptors may increase glutamate activity, raise
intracellular Ca2+ concentration and promote excitotoxicity and neuronal damage [194, 195].
Another process contributing to the excessive glutamate activity in AD is the impairment of
glial cells to remove glutamate form the synaptic cleft possibly due to the action of free radicals
on the glutamate transporter 1 (GLT-1) [196]. Glutamatergic activation, in turn, may disrupt
synaptic plasticity promoting long term depression (LTD) and inhibiting long term potentia‐
tion (LTP) of 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid (AMPA) receptor-
mediated synaptic transmission [197]. The associated persistent reduction in the number of
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functional synaptic AMPA receptors reduces fast excitatory transmission and eventually
triggers spine retraction and synaptic loss [198]. Moreover, glutamate receptors are not only
involved in the process of Aβ-mediated synaptic dysfunction but also play important roles in
Aβ production [199, 200].
Based on these observations, several studies have been designed in an attempt to correct
glutamatergic  dysfunction in AD, including the modulation of  both AMPA and NMDA
receptors [201]. First attempts were carried out with AMPAKines [202], which are drugs
that  prolong the action of  glutamate on AMPA receptors by increasing their  sensitivity.
Interestingly,  AMPAKines  proved  effective  in  restoring  cognitive  deficits  in  aging  rats
[203,  204].  These  compounds  were  tested  in  AD  patients  [205].  The  modulation  of  the
NMDA receptor was assessed via the glycine co-agonist site in rats with disrupted gluta‐
matergic temporal systems resulting in improved learning and memory [206]. Prelimina‐
ry clinical studies suggested some promising effects in AD [207] but full-scale trials have
not yet been initiated.
The most relevant glutamatergic strategy against AD is the non-competitive NMDA antagonist
memantine [201, 208], which has succeeded in clinical trials in moderate and severe AD as
reviewed in detail elsewhere [209, 210]. Several studies performed in animal models of AD
corroborate the beneficial properties of memantine as a symptomatological and neuroprotec‐
tive treatment in AD [211-215]. Nevertheless, memantine has no benefits in cases with mild
AD [216] suggesting that this drug is not a good choice for preventing the progression to
disease states.
2.6.3. Serotonergic system
Loss of serotonergic nerve terminals in AD was described several years ago [217, 218].
Although the suggested serotonergic dysfunction was initially related almost exclusively with
the neuropsychiatric symptoms of AD, including anxiety, irritability, fear and depression,
recent studies have demonstrated that serotonin signaling also plays an important role in
cognition and in the development of Aβ and tau pathologies [219].
Antidepressant  compounds,  acting  through  serotonin  signaling,  result  in  cognitive  im‐
provements  and  reduce  the  levels  of  Aβ  and  tau  pathology  in  animal  models  of  AD
[220, 221]. Similar compounds reduce amyloid burden in humans [221]. Additional sero‐
tonergic  compounds  that  are  currently  being  investigated  in  AD  are  5-hydroxytrypta‐
mine  (5-HT  or  serotonin)  receptors:  5-HT1  and  5-HT6  antagonists,  and  5-HT4  agonists.
The  5-HT1A  antagonist  lecozotan  (SRA-333)  enhances  cognition  in  primates  and  is  now
being tested in AD [222-224].  The pro-cognitive effects  of  5-HT1A  antagonists  are proba‐
bly due to the facilitation of glutamategic and cholinergic transmission after reduction of
the  inhibitory  effects  of  serotonin.  Similarly,  5-HT6  antagonists  improve  cognitive  per‐
formance in animal models and human beings by modulating multiple neurotransmitter
systems [225].  These  properties  mark 5-HT6  antagonists  as  potential  symptomatic  drugs
in AD. In addition, 5-HT4  receptor agonists are neuroprotective, modulating the produc‐
tion of Aβ, and have the property of ameliorating cognitive deficits [226, 227].
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2.7. Synaptic dysfunction
Synaptic dysfunction and failure are processes that occur early in the Alzheimer process
and progress during the course of the disease from an initially reversible functionally-re‐
sponsive stage of down-regulated synaptic function to stages irreversibly associated with
degeneration.
These alterations are manifested early as impaired metabotropic glutamate receptor/phos‐
pholipase C signaling pathway [230] and up-regulation of adenosine receptors in the frontal
cortex in AD [231].
The initial reversible stages are important targets for protective treatments to slow progression
and preserve cognitive and functional abilities [232, 233]. In vivo and in vitro studies have
demonstrated that high levels of Aβ impair structural and functional plasticity of synapses by
affecting the balance between excitation and inhibition and contributing to the destabilization
of neuronal networks, eventually causing synaptic loss [234]. Two main designs have been
proposed to antagonize synaptic plasticity-disrupting actions of Aβ oligomers in preclinical
AD: maintenance of the structure and fluidity of the lipid membranes forming the synaptic
buttons, and stimulation of synaptic plasticity by neurotrophic factors.
Minor changes in the fluidity of phospholipidic membranes might have an important impact
on the function of synapses by influencing neurotransmitter receptor activity. In fact, AD
brains exhibit altered lipid composition of lipid rafts, key membrane microdomains that
facilitate the transfer of substrates and protein-protein and lipid-protein interactions, as a result
of the abnormally low levels of n-3 long-chain polyunsaturated fatty acids, mainly docosa‐
hexaenoic acid (DHA), increasing viscosity and energy consumption and contributing to
synaptic dysfunction [142, 235]. Abnormal lipid raft composition may also modify the activity
of key enzymes that modulate the cleavage of APP to form toxic Aβ. Thus, the preservation of
adequate membrane composition has become an alternative way to prevent the deleterious
effect of Aβ at the synapses. DHA is a major lipid constituent of synaptic end-sites and its
delivery is a prerequisite for the conversion of nerve growth cones to mature synapses [236].
Numerous epidemiological studies have highlighted the beneficial influence of DHA on the
preservation of synaptic function and memory capacity in aged individuals or after Aβ
exposure, whereas DHA deficiency is presented as a risk factor for AD [237]. Moreover, a
number of studies have reported the beneficial effects of dietary DHA supplementation on
cognition and synaptic integrity in various AD models [238]. According to thes evidence, DHA,
which can be synthesized or obtained directly from fish oil, appear to be one of the most
valuable diet ingredients whose neuroprotective properties contribute to preventing AD.
Cytidine 5'-diphosphocholine, CDP-choline, or citicoline is an essential intermediate in the
biosynthetic pathway of structural phospholipids in cell membranes, particularly phosphati‐
dylcholine. Chronic administration has been beneficial in patients with mild cognitive
impairment [239].
Another emerging potential line to preserve synaptic function is the targeting of scaffolding
proteins that modulate neurotransmitter receptor activity at the synapses. Scaffolding proteins
stabilize post-synaptic receptors at the spines in close proximity to their intracellular signaling
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proteins, phosphatases and kinases, thereby facilitating signal-transduction cascades. Evi‐
dence from in vitro cell and animal models of AD indicates that reductions in the post-synaptic
density membrane-associated guanylate kinase (PSD-MAGUK) proteins are linked to synaptic
dysfunction that might trigger plastic changes at early stages of the Alzheimer process [240].
However, specific molecules that affect interactions between scaffolding proteins and neuro‐
transmitter receptors are still in development and further research is necessary to evaluate
their potential benefit in AD.
2.8. Neurotrophic factors
Neurotrophins represent a family of proteins that play a pivotal role in the mechanisms
underlying neuronal survival, differentiation, modulation of dendritic branching and den‐
dritic spine morphology as well as synaptic plasticity and apoptosis [241]. All the members of
the neurotrophin family, including NGF, brain-derived neurotrophic factor (BDNF) and
neurotrophins 3 to 7, transduce their biological effects by interacting with two types of cell
surface receptors, the tyrosine kinase receptor (Trk) and the p75 pan-neurotrophin receptor
(p75NTR) [241]. Other growth factor families also related to synaptic plasticity include the
cytokine family of growth factors, the transforming growth factor-β (TGFβ) family, the
fibroblast growth factor family and the insulin-like growth factor family. Evidence accumu‐
lated during recent years suggests that targeting neurotrophic factor signaling can retard nerve
cell degeneration and to some extent preserve synaptic function. The most studied neurotro‐
phic factors in AD are NGF, BDNF and TGFβ1.
• NGF: Mature basal forebrain cholinergic neurons are highly dependent on the availability
of NGF for the maintenance of their biochemical and morphological phenotype, and for
survival after lesions or variegated insults [242, 243]. For this reason, exploitation of NGF
activity on cholinergic neurons may provide an attractive therapeutic option for preventing
cholinergic cell degeneration in AD. Levels of proNGF, the precursor form of NGF, are
highly elevated in AD brains and animal models, a feature that may be associated with a
reduced conversion to NGF and augmented degradation of mature NGF. These combined
effects have been interpreted as causative of cholinergic atrophy in AD [244]. A role for
Aβ peptide in the induction of such NGF altered metabolism has been described [245].
Minocycline, a second-generation tetracycline antibiotic known to potentiate NGF activity,
is able to normalize proNGF levels and to reverse the increased activity of the NGF-
degrading enzyme matrix metalloproteinase 9, as well as to increase the expression of iNOS
and microglial activation, leading to improved cognitive behavior in a transgenic mouse
model of AD [245]. Yet a disturbing finding is the demonstration of AD proNGF when
compared to proNGF of control individuals [246-248]. Whether this abnormal form of AD-
related proNGF has any impact on the pathogenesis of AD needs further investigation.
Another putative therapy is the use NGF, but NGF does not readily cross the BBB and
requires intra-cerebroventricular infusion to reach targeted brain areas. Pilot clinical trials
were discontinued because of the side-effects of NGF infusions [249]. Therefore, the
development of NGF therapy is constrained by the need to achieve adequate concentrations
in the relevant brain areas with susceptible target neurons while preventing unwanted
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adverse effects in non-target regions or cells. Alternative strategies that are currently under
development include gene therapy and nasal delivery of recombinant forms of NGF, the
use of small molecules with NGF agonist activity, NGF synthesis inducers, NGF processing
modulators, and proNGF antagonists [250].
• BDNF: This neurotrophin is normally produced in the cerebral cortex with high levels in
the entorhinal cortex and hippocampus in adulthood [241]. BDNF levels are reduced in the
cerebral cortex and hippocampus in AD [251-254]. Several studies have shown beneficial
effects of BDNF in animal models of AD [255]. For instance, sustained BDNF gene delivery
using viral vectors after disease onset resulted in elevated BDNF levels in the entorhinal
cortex and hippocampus which were associated with improvement in learning and
memory, and with restoration of most genes altered as a result of mutant APP expression
in that specific transgenic mice model [256]. Similar results were obtained in a different
mouse model of AD, and in aged rats and primates by using distinct BDNF delivery systems
[256, 257]. It is worth pointing out that BDNF did not change β-amyloid plaque density in
any case suggesting that the therapeutic effects of BDNF occur independently of direct
action on APP processing. However, the multiple variegated effects of BDNF on neuronal
function also raise the hypothetical possibility that unintended adverse effects of BDNF may
limit its clinical efficacy in AD [256]. An additional point must be considered; BDNF
signaling pathway is also altered in AD as TrkB expression is reduced and truncated TrkB
is highly expressed in astrocytes at least in advanced stages of the disease [251]. Therefore,
regarding BDNF function in AD, there is not only an alteration in the expression of BDNF
but also an impaired downstream pathway that may corrupt the signal of the trophic factor
acting on inappropriate receptors. Preliminary clinical trials are currently in progress to
evaluate the safety and efficacy of BDNF.
• TGFβ1:  Astrocytes and microglia are the major sources of TGF-β1 in the injured brain
[258, 259]. Impaired TGF-β1 signaling has been demonstrated in AD brain, particularly
at the early phase of the disease; this is associated with Aβ pathology and neurofibril‐
lary  tangle  formation  in  animal  models  [260].  Reduced  TGF-β1  seems  to  induce
microglial activation [259] and ectopic cell-cycle re-activation in neurons [261]. Several
drugs  may  induce  TGF-β1  release  by  glial  cells,  including  estrogens  [262],  mGlu2/3
agonists [263], lithium [264], the antidepressant venlafaxine [265] and glatiramer, which
is a synthetic amino acid co-polymer currently approved for the treatment of multiple
sclerosis [266]. All of them have neuroprotective effects in different in vitro and in vivo
models of AD pathology [260]. Additionally, small molecules with specific TGF-β1-like
activity are being developed as neuroprotectors [267].
A final point must be considered. A generalized sprouting is produced around β-amyloid
deposits in senile plaques in both humans and in animal models [268-270]. The reasons for
such sprouting are not well defined but amyloid species may play a trigger role. In any case,
trophic factors might increase aberrant sprouting at the senile plaques through receptors
expressed at these localizations.
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2.9. Autophagy
Autophagy is a catabolic process occurring in all cell types in which the machinery of the
lysosome degrades cellular components such as long-lived or damaged proteins and organ‐
elles. Thus, a failure of autophagy in neurons results in the accumulation of aggregate-prone
proteins that might exacerbate neurodegenerative process [271, 272]. Autophagy is also
implicated in the accumulation of altered mitochondria and polymorphous inclusions in the
dystrophic neurites around amyloid plaques [273-278].
Indeed, autophagic dysfunction is implicated in the progression of Alzheimer from the earliest
stage, when a defective lysosomal clearance of autophagic substrates and impaired autophagy
initiation occurs and leads to massive buildup of incompletely digested substrates within
dystrophic axons and dendrites [279]. The pharmacological induction of ‘preserved’ autoph‐
agy might enhance the clearance of intracytoplasmic aggregate-prone proteins and therefore
ameliorate pathology [272]. Attempts to restore more normal lysosomal proteolysis and
autophagy efficiency in mouse models of AD pathology have revealed promising therapeutic
effects on neuronal function and cognitive performance, demonstrating the relevance of the
failure of autophagy in the pathogenesis of AD, and the potential of autophagy modulation
as a therapeutic strategy. Autophagy induction with the mTOR-inhibiting drug rapamycin in
young mice resulted in a reduction in Aβ plaques, NFT and cognitive deficits in the adulthood
in two different models of AD [280-283]. Interestingly, rapamycin did not alter any of those
parameters when administered in old animals once the pathology was established, highlight‐
ing the importance of early treatmenting in the disease progression [282]. However, the kinase
mTOR plays an important role in multiple signaling pathways apart from negatively regulat‐
ing autophagy [284]. Therefore, rapamycin treatment is also a putative inducer of undesirable
side-effects. Other drugs including lithium, sodium valproate and carbamazepine acting have
ben proved to induce autophagy through the inhibition of of inositol monophosphatase in an
mTOR-independent pathway [285]. These compunds reveal positive effects by reducing the
accumulation and toxic effects of aggregation-prone proteins in cell models as well as by
protecting against neurodegeneration in in vivo models of Huntington’s disease [286]. Further
research is needed to learn whether they can also be useful tools in the treatment of AD.
2.10. Multi-target treatments
Considering the multifactorial etiology of AD, and the numerous and complex pathologi‐
cal  mechanisms  involved  in  the  progression  of  the  disease,  it  is  quite  reasonable  that
treatments  targeting  a  single  causal  or  modifying  factor  may  have  limited  benefits.
Therefore,  growing  interest  is  focused  on  therapeutic  agents  with  pleiotropic  activity,
which will be able to target, in parallel, several processes affected in AD [287, 288]. Sev‐
eral compounds already mentioned in the previous sections fulfill  these properties,  such
as  DHA  which  presents  anti-inflammatory,  anti-oxidant,  neuroprotective  and  anti-tau
phosphorylation  properties  apart  from  the  modulation  of  synaptic  membrane  composi‐
tion [289],  and curcumin, which in addition to anti-oxidant properties also exhibits anti-
inflammatory  and  Aβ-  and  tau-binding  properties  [106].  Similarly,  rosiglitazone  and
dimebon are known to produce beneficial effects through insulin receptor signaling mod‐
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ulation  and  mitochondrial  protection  [153,  165].  Other  multi-target  potential  treatments
currently under development for AD are based on the use of the following compounds:
• Caffeine: This is one of the most consumed psychoactive drugs which mainly acts blocking
adenosine receptors 1 and 2 [290, 291]. In addition, caffeine reduces amyloid burden in
animal models of AD [292, 293]. Epidemiological studies in humans have also shown
protection against cognitive decline [294-296].
• Estrogen: This steroid hormone is known to play an important role in neuronal survival,
mitochondrial function, neuroinflammation and cognition, with important neuroprotective
effects [297-299]. Some of the neuroprotective actions mediated by estrogens are related to
the insulin-like growth factor-1 (IGF-1) signaling pathway [300]. Several studies in animal
models of AD have revealed therapeutic properties of estrogen against the progression of
the disease. For instance, the treatment of ovariectomized 3xTg-AD mice with estrogen
resulted in prevention of the increased Aβ accumulation and worsening memory perform‐
ance induced by the depletion of sex steroid hormones [301]. Clinical and epidemiological
studies in AD support the beneficial effets of estrogens [302]. However, a critical factor for
success in estrogen therapy for AD is the age at the initiation of the treatment; the efficacy
of estrogens is greatest in younger women and in women who initiated the estrogen therapy
at the time of menopause [303].
• Cannabinoids: The natural compounds derived from Cannabis sativa or synthetic compounds
acting on endogenous cannabinoid system have emerged as potential agents against several
neurodegenerative processes [305]. Cannabinoids offer a multi-faceted approach for the
treatment of AD as the stimulation of the widely brain-expressed cannabinoid receptors
provides neuroprotection against Aβ [305, 306] and reduces neuroinflammation [306-308]
and tau phosphorylation [306, 309] in AD-like transgenic mice. In addition, cannabinoids
support brain repair mechanisms by augmenting neurotrophin expression and enhancing
neurogenesis [310]. Moreover, cannabinoids are able to reduce Aβ-dependent oxidative
stress [311] and Aβ-mediated lysosomal destabilization related to apoptosis [312]. In
addition, some cannabinoids are able to inhibit acetylcholinesterase activity [313]. It is worth
stressing that molecular achievements of cannabinoids are accompanied by cognitive
improvement and reduction of several degenerative markers in two different animal models
of AD [306, 308]. Examination of the potential beneficial effects of chronic administration of
low doses of cannabinoids with little psychotropic effect at early stages of the degenerative
process in humans seems very promising.
• Erythropoietin (EPO) and derivatives: EPO is effective in neuroprotection against ischemia and
traumatic brain injury [314]. In addition, animal studies reveal that EPO both reduces tau
phosphorylation through modulation of PI3K/Akt-GSK-3beta pathway [315] and protects
against Aβ-induced cell death through anti-oxidant mechanisms [316]. An additional
characteristic of EPO that confers potential utility in AD is the specific effect on cognition:
EPO enhances hippocampal LTP and memory by modulating plasticity, synaptic connec‐
tivity and activity of memory-related neuronal networks [317]. In spite of these benefits,
chronic administration of EPO is problematic because of the concomitant excessive eryth‐
ropoiesis. In this sense, some new derivatives of EPO that do not bind to the classical EPO
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receptor (carbamylated EPO) or that have such a brief half-life in the circulation that they
do not stimulate erythropoiesis (asialo EPO and neuro EPO) have demonstrated neuropro‐
tective activities without the potential adverse effects on circulation associated with EPO
[318]. Therefore, these new compounds are considered as potential treatments in AD.
• Statins: Evidence has accumulated that a high cholesterol level may increase the risk of
developing AD and that the use of statins to treat hyper-cholesterolemia is useful in treating
and preventing AD [319]. Statins reduce the production of cholesterol and isoprenoid
intermediates. These isoprenoids modulate the turnover of small GTPase molecules that are
essential in numerous cell-signaling pathways, including vesicular trafficking and inflam‐
mation [320]. Thus, statins reduce the production of Aβ by disrupting secretase enzyme
function and by curbing neuroinflammation in experimental models of AD [321, 322].
• Ladostigil is a dual acetylcholine-butyrylcholineesterase and brain selective monoamine
oxidase (MAO)-A and -B inhibitor in vivo. Interest in this compound in AD treatment
research is sustained by the potential increase in brain cholinergic activity properties but
also by the capacity of ladostigil to prevent gliosis and oxidative-nitrosative stress damage.
Moreover, ladostigil has been demonstrated to possess potent anti-apoptotic and neuro‐
protective properties in vitro and in various neurodegenerative animal models including
AD transgenic mice [323]. These neuroprotective activities involve regulation of APP
processing, activation of protein kinase C and mitogen-activated protein kinase signaling
pathways, inhibition of neuronal death markers, prevention of the fall in mitochondrial
membrane potential, up-regulation of neurotrophic factors, and anti-oxidative activity.
• Huperzine A is an extract of the Chinese plant Huperzia serrata. Huperzine A is a selective
potent inhibitor of AChE [324]. In addition, some studies have shown that huperzine A may
shift APP metabolism towards the non-amyloidogenic α-secretase pathway [325]. In
addition, huperzine A reduces glutamate-induced cytotoxicity by antagonizing cerebral
NMDA receptors [326]. Finally, huperzine A reverses or attenuates cognitive deficits in
some animal models of AD [325]. Large-scale, randomized, placebo-controlled trials are
necessary to establish the role of huperzine A in the treatment of AD [327].
• Phytochemicals as curcumin, catechins and resveratrol beyond their antioxidant activity are
also involved in antiamyloidogenic, anti-inflammatory mechanisms and inhibitors of
NFkappaB [328-330].
• Celastrol is another compound whicha appears to have multiple functions as anti-inflam‐
matory, anti-oxidant and reductor of amyloouid via BACE 1 [331, 332].
3. Concluding remarks
Main targets of therapeutic intervention at early stages of Alzheimer are summarized in Figure
1. Based on the presently available data several conclusions can be drawn. Combination
therapies with drugs targeting different pathological factors or the use of multi-target com‐
pounds appear to be the most effective strategy in the treatment of the neurodegenerative
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process in Alzheimer. Most potential experimental therapies exhibit the highest efficiency
when applied during the pre-symptomatic phase of the disease. Therefore, it is essential to
develop diagnostic tools to detect Alzheimer at early stages. Moreover, considering that
Alzheimer, as a degenerative process not necessarily leading to dementia, affects a large
percentage of individuals in the sixth decade of life, it would be wise to introduce habits and
low-cost, safe treatments to prevent the progression of Alzheimer early in life, as occurs in
artheriosclerosis, to transform AD into a chronic, incomplete and non-devastating disease
thereby allowing for normal life in the elderly.
Figure 1. Schematic representation of the main cellular targets that are currently under development to prevent or
retard the progression of Alzheimer to disease states. Most of the experimental approaches are designed to block or
mitigate (red lines) pathological events occurring at the earliest stages, including abnormal Aβ and tau aggregation,
chronic inflammatory responses, and oxidative stress damage. Other strategies (blue lines) aim at stimulating the me‐
tabolism to reduce Alzheimer’s energetic failure as well as to promote intrinsic mechanisms that protect or repair cel‐
lular damage, including synaptic plasticity, preservation of the lipid membrane composition, and the promotion of
damaged protein and organelle turnover. Therapeutic approaches based on the modulation of neurotransmission
(green dashed lines) are designed to bypass deficient cholinergic neurotransmission whereas other compounds aim to
block glutamatergic excitotoxicity. Considering the complex scenario of the Alzheimer neurodegenerative process,
multi-target therapies applied at early stages of the disease appear to be the most effective strategy.
In  addition  to  these  general  conclusions,  several  points  deserve  a  particular  comment.
Recognition  of  the  genotypic  background,  clinical  and  neuropathological  subtypes  and
different  pace  of  clinical  manifestations  is  important  to  refine  personalized  treatments
[333-335].  This includes modifications of the treatment as Alzheimer is not a mere accu‐
mulation of defects but rather a combination of deficiencies and plastic changes that im‐
ply  shifts  in  molecular  pathways  with  disease  progression.  Drugs  and  treatments
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beneficious  at  first  stages  of  the  degenerative  process  may  be  harmful  at  advanced
stages.  Special  effort  must  be put  into practice  to learn about the combination of  drugs
at which determinate time for every particular individual.
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